Fundraising Fox
KDx Diagnostics
Campbell, US · Founded 2016 · Delaware corporation
Find your way into KDx Diagnostics
Sign up to see every warm intro you have to KDx Diagnostics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the KDx Diagnostics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
KDx Diagnostics develops diagnostic tests for early detection and management of cancer, including the URO17 non-invasive urine test for bladder cancer based on the Keratin 17 biomarker. The URO17 test is offered in the US as a Laboratory Developed Test through reference laboratories and as a CE-IVD kit outside the US.
Founders & leadership
KDx Diagnostics was founded in 2016 by Shahram Shawn Gholami.
SS
NK
Nam KimChief Executive Officer & Chief Technology OfficerNam Kim is an R&D scientist and biotech executive with over 30 years of experience in pharmaceuticals and biotechnology, with expertise in biomarker discovery, molecular diagnostics, and translational medicine across oncology and other therapeutic areas.
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 4 rounds · 2017–2019
▶$820KraisedMay 2019 · 16 investors · BiotechnologyRule 506(b)
▶$820KraisedMay 2019 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $820K
- Minimum investment
- $10K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$300KraisedMar 2019 · 2 investors · BiotechnologyRule 506(b)
▶$300KraisedMar 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $300K
- Minimum investment
- $100K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$100KraisedAug 2018 · 2 investors · BiotechnologyRule 506(b)
▶$100KraisedAug 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $100K
- Minimum investment
- $20K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$440KraisedDec 2017 · 6 investors · BiotechnologyRule 506(b)
▶$440KraisedDec 2017 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $440K
- Minimum investment
- $20K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
MD Anderson Cancer CenterUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Fred HutchFred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.
Companies working in the same space as KDx Diagnostics.
Frequently asked questions
- What does KDx Diagnostics do?
- KDx Diagnostics develops diagnostic tests for early detection and management of cancer, including the URO17 non-invasive urine test for bladder cancer based on the Keratin 17 biomarker. The URO17 test is offered in the US as a Laboratory Developed Test through reference laboratories and as a CE-IVD kit outside the US.
- Who founded KDx Diagnostics?
- KDx Diagnostics was founded by Shahram Shawn Gholami in 2016.
- How much funding has KDx Diagnostics raised?
- KDx Diagnostics has disclosed $1.7M raised across 4 rounds.
- Where is KDx Diagnostics headquartered?
- KDx Diagnostics is headquartered in Campbell, US.